NEW YORK (GenomeWeb News) – The US Food and Drug Administration today said it has cleared Affymetrix’s CytoScan Dx Assay for marketing in the US.

The assay can detect chromosomal variations that may be responsible for developmental delay or intellectual disability in children. The test analyzes an entire genome at one time and detects large and small chromosomal changes, based on a blood sample, FDA said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.